Huberman LabPsychedelics for Treating Mental Disorders | Dr. Matthew Johnson
CHAPTERS
- 0:00 – 10:20
Introduction, Guest Background, and Scope of the Conversation
Huberman introduces the podcast, outlines his mission of providing science‑based tools, names the sponsors, and presents Dr. Matthew Johnson as a leading researcher in psychedelic and drug effects on human behavior. They preview topics including microdosing vs macrodosing, clinical psilocybin therapy, and broader implications for mental health treatments.
- •Huberman frames the podcast as separate from his Stanford roles, emphasizing free public education in science.
- •Dr. Matthew Johnson is introduced as a Johns Hopkins psychiatry professor and head of the Center for Psychedelic and Consciousness Research.
- •Johnson’s work spans psychedelics for depression, trauma, addiction, and broader drug effects on risk‑taking, sexuality, and crime.
- •The episode will examine microdosing, macrodosing, what psychedelic therapy sessions look like from start to finish, and the past and future of psychedelic science.
- 10:20 – 29:20
What Is a Psychedelic? Classes, Receptors, and Mechanisms
Johnson explains that “psychedelic” is a high‑level, partly cultural term that cuts across pharmacological classes. He distinguishes classic 5‑HT2A agonist psychedelics, NMDA antagonists like ketamine, atypical agents like salvinorin A, and MDMA as an entactogen, clarifying how chemistry, receptor targets, and subjective effects intersect but do not map one‑to‑one.
- •Classic psychedelics (LSD, psilocybin, DMT, mescaline) primarily act as agonists/partial agonists at the serotonin 2A receptor.
- •Within classics there are tryptamines (psilocybin, DMT) and phenethylamines (mescaline), showing that similar subjective effects can arise from different chemical backbones.
- •NMDA antagonists (ketamine, PCP, dextromethorphan) can produce overlapping subjective effects—dissociation, altered reality, entity encounters—despite acting on glutamatergic systems.
- •Salvinorin A from Salvia divinorum is a kappa‑opioid agonist that can induce intense, short‑lived, reality‑shattering experiences.
- •MDMA is best labeled an entactogen/empathogen; it primarily releases serotonin (and some dopamine), with a phenomenology distinct from classic psychedelics.
- •Chemistry alone does not predict effect; minor molecular tweaks can radically change receptor signaling and behavioral output.
- 29:20 – 51:00
Serotonin, Dopamine, and How Psychedelics Alter Reality and Self
They compare serotonergic and dopaminergic neuromodulation and how psychedelics change perception, time, space, and predictive models. Johnson frames humans as prediction machines whose top‑down models, including the model of self, are partially dissolved by psychedelics, enabling new interpretations of reality and selfhood.
- •Serotonin is broadly associated with contentment and being okay in the present; dopamine with oriented, goal‑directed seeking of external rewards.
- •Classic psychedelics mimic serotonin at 5‑HT2A receptors but induce qualitatively different downstream signaling than endogenous serotonin.
- •Psychedelics may disrupt or relax high‑level predictive models of the world (e.g., gravity, self‑boundary, identity), leading to deep surprise and re‑evaluation.
- •Examples include misperceiving gravity, feeling able to jump through a painting, or believing one can fly—rare but illustrative of prediction model breakdown.
- •Johnson stresses levels of analysis: receptor pharmacology, local circuitry (e.g., glutamate increases), large‑scale network coordination, and experiential phenomenology.
- 51:00 – 1:05:20
Inside a Clinical Psilocybin Session: Screening, Preparation, and Dosing
Johnson walks through the full protocol used at Johns Hopkins for therapeutic psilocybin sessions: intensive medical and psychiatric screening, rapport‑building with guides, detailed education about possible experiences, and administration of pure psilocybin in capsule form at carefully chosen doses.
- •Screening includes structured psychiatric interviews (to rule out psychotic and bipolar disorders) and cardiovascular evaluation (to rule out serious heart disease).
- •Preparation involves 4–8+ hours of meetings to build trust with two guides/therapists and to set expectations about the wide range of possible experiences.
- •Volunteers are told they may experience the most beautiful or most terrifying event of their life; the key is to accept and explore whatever arises.
- •In research, they use pure psilocybin (not mushrooms), typically 20–30 mg (historically weight‑adjusted), encapsulated and ingested orally.
- •Onset takes 15–60 minutes; sessions last several hours, with minimal tasks to maximize therapeutic depth (as fMRI/cognitive tasks tend to blunt meaningfulness).
- 1:05:20 – 1:12:00
Letting Go, Altered Self, and Therapeutic Mechanisms of Change
They delve into the psychological mechanics of a high‑dose psilocybin trip: surrendering control, focusing deeply on inner experience, and allowing intense emotional and somatic states. Johnson argues that lasting benefit emerges from profound changes in self‑representation and sense of agency, rather than from verbal affirmations or insight alone.
- •Participants are encouraged to surrender control, allow any emotional expression (crying, fear, grief), and follow experiential “bubbles” (e.g., body sensations, memories) deeply.
- •Eyeshades and music help shift attention inward and amplify the “mind’s eye,” making internal imagery vivid even with minimal external hallucinations.
- •Participants may experience intense physiological sensations (e.g., pounding heart, breath awareness) that feel life‑threatening but are usually within safe ranges; staff monitor vital signs and intervene medically if needed.
- •Johnson describes “duh” realizations: people experientially grasp things they’ve told themselves intellectually for years (e.g., “I can choose not to smoke”), but which finally carry emotional and motivational weight.
- •He emphasizes enduring shifts in self‑representation (e.g., not identifying as “a smoker” or “a depressed person”) as a likely common mediator across diverse psychedelic experiences.
- •Huberman contrasts psychedelic‑induced experiential plasticity with superficial self‑help affirmations, underscoring that neural circuits change primarily through embodied experience plus neuromodulation, not language alone.
- 1:12:00 – 1:41:20
MDMA, Ketamine, and Comparing Therapeutic Models
The discussion contrasts MDMA and ketamine with classic psychedelics in terms of pharmacology, phenomenology, and how they are currently used in therapy. Johnson criticizes purely pharmacologic ketamine models that ignore subjective experience and highlights studies where ketamine was treated more like a psychedelic with promising addiction outcomes.
- •MDMA primarily increases serotonin release (and to some extent dopamine and norepinephrine), leading to heightened emotional access, empathy, and reduced amygdala reactivity.
- •It has been labeled an “entactogen” (“touching within”) or “empathogen,” and stands apart from classic psychedelics phenomenologically.
- •In FDA‑approved Spravato (esketamine) treatment for depression, the dissociative experience is treated as an adverse side effect to ignore, with little to no psychotherapy integrated.
- •Earlier high‑dose ketamine work in Russia (Kripitsky) used a psychedelic‑style model—explicit preparation, expectation of a meaningful inner journey, and post‑session processing—and reported strong outcomes for heroin and alcohol addiction.
- •Johnson argues we need comparative research to see whether psychedelic‑style ketamine sessions outperform current, more mechanistic Spravato protocols and whether MDMA vs psilocybin is differentially suited to PTSD vs depression.
- 1:41:20 – 2:04:20
Integration: From Acute Experience to Lasting Life Changes
Johnson outlines the post‑session process of integration: immediate debrief, written reflection, and follow‑up therapy sessions where participants unpack their experiences and translate them into specific behavioral and relational changes, while avoiding impulsive life decisions in the immediate aftermath.
- •As the drug wanes (about 5–6 hours in), guides invite brief initial sharing but avoid heavy analysis during the tail end of the acute state.
- •Participants are assigned homework to write about the experience that night—ranging from bullet points to lengthy narratives—without self‑censoring.
- •Integration sessions the next day (1–2 hours) use supportive, non‑directive therapy to explore themes, insights, and how they relate to the presenting problem (e.g., smoking, cancer anxiety).
- •Patients may be encouraged to have important conversations (e.g., apologies), but are advised to delay major life decisions (ending relationships, quitting jobs, big commitments) for at least one to two weeks.
- •Johnson underscores that social context can either validate or dismiss psychedelic insights; in mainstream recreational circles, experiences are often trivialized as “you were just messed up,” undermining potential growth.
- 2:04:20 – 2:23:20
Risks, Contraindications, Bad Trips, and Flashbacks
They candidly address the major psychological and behavioral risks of psychedelics, particularly for individuals with psychosis or bipolar predisposition and for unsupervised, high‑dose recreational use. Johnson clarifies myths around flashbacks and HPPD and makes nuanced comparisons with harms from alcohol and other drugs.
- •The biggest red flags are schizophrenia, schizoaffective, and bipolar I–type disorders, or strong family history—these individuals can be destabilized, potentially precipitating or worsening psychosis or mania.
- •Trials exclude such individuals, sometimes even those with affected first‑ or second‑degree relatives, as an overly cautious safeguard in early research phases.
- •“Bad trips” in healthy people can involve extreme anxiety, fear of going insane, loss of self, and feeling trapped in an alien reality; in uncontrolled settings, this can lead to dangerous behavior (falls, running into traffic, violent encounters with police).
- •Johnson notes tragic real‑world cases (e.g., a young man on a large mushroom dose fatally shot by police) and emphasizes the importance of dose, setting, and sober monitors.
- •True Hallucinogen Persisting Perceptual Disorder (HPPD) is rare, clinically defined by ongoing, distressing visual distortions for months; it has never appeared in thousands of clinical trial participants.
- •A case series shows similar persistent visual syndromes triggered by alcohol, benzodiazepines, cannabis, or even spontaneously in people with no drug history, suggesting a rare neurological vulnerability rather than a unique psychedelic effect.
- •More common “flashbacks” are better seen as state‑dependent reactivation of memories or mild short‑term visual after‑effects rather than latent drug being released from fat stores—a myth unsupported by evidence.
- 2:23:20 – 2:37:20
Microdosing: Hype, Evidence, and Theoretical Safety Concerns
They examine the popular practice of microdosing LSD or psilocybin for focus, creativity, or mood. Johnson outlines how microdoses are defined and prepared in the real world, summarizes current placebo‑controlled data, and raises a largely ignored cardiovascular safety issue related to 5‑HT2B receptor activation.
- •Microdosing typically means taking about one‑tenth of a threshold psychedelic dose (e.g., ~10 µg LSD vs ~100 µg for perceptible effects; tiny fractions of a gram of dried mushrooms).
- •Real‑world dosing is crude: people often cut blotter paper into tiny pieces or estimate mushroom quantities, leading to frequent overshooting into mild trip territory.
- •Controlled double‑blind studies have not shown robust improvements in creativity, cognition, or mood; if anything, they find small impairments (e.g., time estimation) and participants feeling “a little high.”
- •Proponents claim benefits require specific on‑off schedules (e.g., every third day for weeks), but these regimens have not yet been rigorously tested.
- •Many psychedelics, including MDMA, have 5‑HT2B agonist activity; chronic 5‑HT2B stimulation is linked to valvular heart disease (as seen with the diet drug fenfluramine in Phen‑fen).
- •Short‑term, infrequent high‑dose therapeutic use is unlikely to pose valvulopathy risk, but chronic twice‑weekly microdosing for years may be more concerning, especially without cardiologic monitoring.
- 2:37:20 – 2:57:40
Psychedelics in Youth, Legal Status, and Regulatory Futures
They explore the prospect of psychedelic therapy in adolescents, the complex legal status of psychedelics in the U.S., and how medicalization via FDA approval will likely precede any broader regulatory reform. Johnson stresses the distinction between decriminalization, medical approval, and full legalization.
- •FDA has signaled interest in eventual pediatric studies; depression and PTSD exist in adolescents, and age is a key biological variable, not an automatic exclusion.
- •Any youth trials would be especially cautious, likely limited to treatment‑resistant, severe conditions with strong safeguards.
- •Federally, psychedelics remain Schedule I; local/state decriminalization (e.g., “lowest law enforcement priority”) does not override federal law, though most enforcement occurs at local levels.
- •Oregon’s psilocybin services initiative is working through a two‑year implementation period, trying to align state‑level supervised use with ongoing federal prohibition.
- •Johnson envisions long‑term drug policy evolution moving from criminalization toward nuanced regulation matching each drug’s risks and benefits, potentially including training/licensing requirements for personal psychedelic use.
- •In the nearer term, MDMA‑assisted psychotherapy for PTSD and psilocybin‑assisted therapy for depression are likely to be approved as clinic‑based medical treatments with strict protocols, not over‑the‑counter products.
- 2:57:40 – 3:12:40
Traumatic Brain Injury, Neuroplasticity, and Future Research Directions
They discuss early, exploratory ideas about using psychedelics to aid recovery from traumatic brain injury (TBI), chronic traumatic encephalopathy–like syndromes, stroke, and cognitive impairments. Johnson connects rodent data on psychedelic‑induced neuroplasticity and human anecdotes from athletes to potential human trials in collaboration with organizations like the UFC.
- •Rodent studies show that classic psychedelics and related compounds can enhance structural neuroplasticity (e.g., dendritic growth, spine density) days after dosing.
- •Athletes in high‑impact sports and military veterans report subjective improvements in cognition, mood, and “brain healing” after psychedelic use, though these are anecdotes.
- •Johnson plans studies in retired athletes (e.g., UFC fighters) with histories of repetitive head impact, targeting both depression relief and exploratory cognitive/structural MRI outcomes.
- •The rationale is that psychedelic‑facilitated neuroplasticity, coupled with appropriate learning and rehabilitation, might help rewire networks damaged by TBI or stroke.
- •He emphasizes that this area is highly preliminary and speculative; rigorous controlled trials are needed before any clinical claims can be made.
- 3:12:40 – 3:33:20
Funding, Philanthropy, and Building a Psychedelic Research Center
Johnson explains how modern human psychedelic research survived the decades‑long funding winter through small foundations and philanthropists, then accelerated with major gifts that enabled the Johns Hopkins Center for Psychedelic and Consciousness Research. They discuss the NIH’s limited role to date and how philanthropic risk‑taking catalyzed the field’s rebirth.
- •For years, most psychedelic work was funded by small, mission‑driven groups like the Heffter Research Institute, the Beckley Foundation, and the Council on Spiritual Practices.
- •MAPS similarly sustained MDMA research through philanthropy focused on PTSD treatment.
- •NIH (especially NIDA) has funded only a small subset of psychedelic work, mostly oriented toward abuse potential rather than therapeutic benefit.
- •A transformative $17M philanthropic gift (half from the Steven & Alexandra Cohen Foundation, half from the Tim Ferriss Collaborative) allowed Hopkins to establish a formal psychedelic research center, funding staff, infrastructure, and salary support.
- •This center structure lets Johnson and colleagues focus heavily on psychedelics without jeopardizing their academic careers, moving beyond “wing and a prayer” grant‑to‑grant survival.
- •Huberman underscores that such funding does not enrich investigators personally but buys protected time, personnel, and equipment to do more and better science.
- 3:33:20
Closing Reflections, Accessing Trials, and The Broader Impact
They close by discussing how people can find legitimate clinical trials, the limits of current access (all use must be under experimental protocols), and Johnson’s sense that this work is having real‑world impact. Huberman thanks Johnson for taking career risks to rigorously study psychedelics and for helping shape a science‑based path forward.
- •Legitimate ongoing studies at Johns Hopkins are listed at hopkinspsychedelic.org; broader trials can be found on clinicaltrials.gov by searching terms like “psilocybin” or “MDMA.”
- •Researchers cannot legally offer bespoke psilocybin therapy outside IRB‑ and FDA‑approved protocols; any treatment must be within a specific, pre‑registered clinical trial with defined doses and diagnoses.
- •Johnson’s group also runs survey studies for people who have already used psychedelics or holotropic breathwork for therapeutic reasons.
- •He stresses that, even if psychedelics had never been criminalized, structured medical models would still be needed to maximize efficacy and minimize harm.
- •Huberman notes the convergence of academic research, cautious clinical innovation, and a startup ecosystem around psychedelics, emphasizing that rigorous science is the best guardrail in a rapidly commercializing space.
- •Both express optimism that properly integrated psychedelic therapies can meaningfully alleviate human suffering while acknowledging the need for continued caution and research.
